Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV
The Readout Loud
00:00
TREDELVI - Is Tredelvi a Cancer Drug?
Despite a qone positive study, gilliad's stock price fell as investors sussed out that tredelvi was unlikely to grow into the block buster cancer drug. This is one of three big deals that have gone bad under the tenure of ceo dan o day since he joined gilead in two thousand and 19. The company paid na 21 billion dollars to buy imunometix and trodelvi to help reach that goal. But as this week's announcement showed, gilead's cancer dreams seemed far away from being realized.
Transcript
Play full episode
